Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy-Reference-Cited by-同舟云学术

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy

Published:2017-07-21 Issue:1 Volume:36 Page:151-155
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bun Seiko,Yonemori Kan,Akagi Toru,Noguchi Emi,Shimoi Tatsunori,Shimomura Akihiko,Yunokawa Mayu,Shimizu Chikako,Fujiwara Yasuhiro,Makino Yoshinori,Hayashi Yoshikazu,Tamura Kenji

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0487-3/fulltext.html

Reference18 articles.

1. Aapro MS (2007) Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 3(6):1009–1020

2. Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol : official journal of the American Society of Clinical Oncology 12(5):1050–1057. doi: 10.1200/jco.1994.12.5.1050

3. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. doi: 10.1002/cncr.11433

4. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical O (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol : official journal of the American Society of Clinical Oncology 29(31):4189–4198. doi: 10.1200/JCO.2010.34.4614

5. Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer : official journal of the Multinational Association of Supportive Care in Cancer 21(6):1655–1663. doi: 10.1007/s00520-012-1710-6

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: A systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology;2024-09-08

2. A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy;Journal of Cancer Research and Clinical Oncology;2024-05-28

3. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study;Supportive Care in Cancer;2018-12-14

4. The latest consensus on antiemetics;Current Opinion in Oncology;2018-07

5. AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis;Journal of Pharmacology and Experimental Therapeutics;2018-03-26